Your browser doesn't support javascript.
loading
Elevated plasma levels of TNF-R1 predict the development of acute ischemic events in coronary patients with diabetes. / Los niveles plasmáticos elevados de TNF-R1 predicen el desarrollo de eventos isquémicos agudos en pacientes coronarios con diabetes.
Mas-Fontao, Sebastián; Tarín, Nieves; Cristóbal, Carmen; Soto-Catalán, Manuel; Pello, Ana; Aceña, Alvaro; Lumpuy-Castillo, Jairo; Garces, Carmen; Gomez-Guerrero, Carmen; Gutiérrez-Landaluce, Carlos; Blanco-Colio, Luis M; Martín-Ventura, José Luis; Huelmos, Ana; Alonso, Joaquín; López Bescós, Lorenzo; Moreno, Juan A; Mahíllo-Fernández, Ignacio; Lorenzo, Óscar; González-Casaus, María Luisa; Egido, Jesús; Tuñón, José.
Afiliación
  • Mas-Fontao S; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España; Faculty of Medicine and Biomedicine, Universidad Alfonso X el Sabio (UAX), Madrid, España.
  • Tarín N; Department of Cardiology, Hospital Universitario de Móstoles, Móstoles, Madrid, España; Faculty of Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, España.
  • Cristóbal C; Faculty of Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, España; Department of Cardiology, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España.
  • Soto-Catalán M; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España.
  • Pello A; Department of Cardiology, IIS-Fundación Jiménez Díaz, Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España.
  • Aceña A; Department of Cardiology, IIS-Fundación Jiménez Díaz, Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España.
  • Lumpuy-Castillo J; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España.
  • Garces C; Lipid Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España.
  • Gomez-Guerrero C; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España.
  • Gutiérrez-Landaluce C; Department of Cardiology, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, España.
  • Blanco-Colio LM; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; CIBERCV, Madrid, España.
  • Martín-Ventura JL; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España; CIBERCV, Madrid, España.
  • Huelmos A; Department of Cardiology, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, España.
  • Alonso J; Faculty of Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, España; Department of Cardiology, Hospital de Getafe, Getafe, Madrid, España.
  • López Bescós L; Faculty of Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, España.
  • Moreno JA; Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Hospital Universitario Reina Sofía, Córdoba, España; Department of Cell Biology, Physiology and Immunology, University of Cordoba, Córdoba, España.
  • Mahíllo-Fernández I; Department of Epidemiology and Biostatistics Research Unit, IIS-Fundación Jiménez Díaz, Madrid, España.
  • Lorenzo Ó; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España.
  • González-Casaus ML; Department of Laboratory Medicine, La Paz University Hospital, Madrid, España.
  • Egido J; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España. Electronic address: jegido@
  • Tuñón J; Renal, Vascular and Diabetes Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, España; Department of Cardiology, IIS-Fundación Jiménez Díaz, Madrid, España; Faculty of Medicine, Universidad Autónoma de Madrid, Madrid, España; CIBERCV, Madrid, España. Electronic address: jtunon@fjd.es.
Article en En, Es | MEDLINE | ID: mdl-39343690
ABSTRACT

OBJECTIVES:

To examine the relationship between inflammatory biomarkers and the occurrence of cardiovascular events in patients with type 2 diabetes mellitus (DM2) and stable coronary artery disease.

METHODS:

A total of 964 patients with stable coronary artery disease were included. Plasma levels of inflammatory markers, including tumour necrosis factor receptors 1 and 2 (TNF-R1 and TNF-R2), growth differentiation factor-15 (GDF-15), soluble suppression of tumorigenicity 2 (sST2), and high-sensitivity C-reactive protein (hsCRP) were measured. The primary endpoint was the development of acute ischaemic events (any type of acute coronary syndrome, stroke, or transient ischaemic attack).

RESULTS:

There were 232 diabetic patients and 732 non-diabetic patients. Patients with coronary artery disease and DM2 (232, 24%) had higher levels of TNF-R1, TNF-R2, GDF-15, sST2 (P<.001), and hsCRP compared to patients without DM2, indicating a higher inflammatory state. After a median follow-up of 5.39 (2.81-6.92) years, patients with DM2 more frequently developed the primary endpoint (15.9% vs 10.8%; P=.035). Plasma levels of TNF-R1 were independent predictors of the primary endpoint in patients with DM2, along with male gender, triglyceride levels, and the absence of treatment with angiotensin-converting enzyme inhibitors. None of these inflammatory markers predicted the development of this event in non-diabetic patients.

CONCLUSIONS:

Patients with stable coronary artery disease and DM2 exhibit elevated levels of the proinflammatory markers TNF-R1, TNF-R2, GDF-15, and sST2. Moreover, TNF-R1 is an independent predictor of acute ischaemic events only in diabetic patients.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En / Es Revista: Clin Investig Arterioscler Año: 2024 Tipo del documento: Article Pais de publicación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En / Es Revista: Clin Investig Arterioscler Año: 2024 Tipo del documento: Article Pais de publicación: España